Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: An NSABP Foundation Research Program phase i study

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 6, 2013, Pages 1205-1212

  Jankowitz, Rachel C ^a,b   Abraham, Jame ^a,c   Tan, Antoinette R ^a,d   Limentani, Steven A ^a,e   Tierno, Marni B ^a   Adamson, Laura M ^a   Buyse, Marc ^a,f   Wolmark, Norman ^a,g   Jacobs, Samuel A ^a  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e CAROLINAS MEDICAL CENTER   (United States)

^f INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^g ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Breast cancer; HER2; Neratinib; Paclitaxel; Phase I; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NERATINIB; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOTENSION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; UREMIA;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; QUINOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84890405678     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2262-2     Document Type: Article

References (32)

1. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
2. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
3. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
4. Robert NJ, Eiermann W, Pienkowski T et al (2007) BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up. J Clin Oncol 25:18s (suppl; abstr 19647)
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
6. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
7. Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639
8. Rusnak DW, Lackey K, Affleck K et al (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94
9. Ritter CA, Perez-Torres M, Rinehart C et al (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13:4909-4919
10. Rabindran SK, Discafani CM, Rosfjord EC et al (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Clin Cancer Res 64:3958-3965
11. Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999-3005
12. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med 355:2733-2743
13. Untch M, Loibl S, Bischoff J et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135-144
14. Hegde PS, Rusnak D, Bertiaus M et al (2007) Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 6:1629-1640
15. Burstein HJ, Sun Y, Dirix LY et al (2012) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28:1301-1307
16. Seyhan AA, Varadarajan U, Choe S et al (2011) A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments. Mol BioSyst 7:1974-1989
17. Chow L, Xu B, Gupta S et al (2013) Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Brit J Cancer 108(10):1985-1993
18. Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N et al (2010) A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 79(1-2):129-135
19. Scaltriti M, Verma C, Guzman M et al (2009) Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28:803-814
20. Sanchez-Martin M, Pandiella A (2011) Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. Int J Cancer 131:244-252
21. Scaltriti M, Rojo F, Ocaña A et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638
22. Scaltriti M, Chandarlapaty S, Prudkin L et al (2010) Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16:2688-2695
23. Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640
24. Swaby R, Blackwell K, Jiang Z et al (2009) Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 27:15s (suppl; Abstr 1004)
25. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32
26. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61-70
27. Rimm D, Ballman KV, Cheng H et al (2012) EGFR expression measured by quantitative immunofluorescence is associated with decreased benefit from trastuzumab in the adjuvant setting in the NCCTG (Alliance) N9831 trial. Cancer Res 72:24s (suppl; abstract S5-4)
28. Neratinib Investigator's Brochure, Version 1.0, 12 Sep 2012
29. Wong KK, Fracasso PM, Bukowski RM et al (2009) A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558
30. Leyland-Jones B, Gelmon K, Ayoub JP et al (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971
31. Baselga J, Schöffski P, Rojo F et al (2006) A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol 24:18s (suppl; abstr 3006)
32. Pectasides D, Gaglia A, Arapantoni-Dadiotti P et al (2006) HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 26(1B):647-653